To determine whether the antileukemic effects of DHE were associated with suppression of expression of intratumoral MYC in vivo, we implemented an alternative xenograft mouse model using subcutaneous engraftment of human AML cells, which is a validated approach for monitoring intratumoral biomarkers of drug response, including suppression of MYC51. The gene discussed is MYC; the disease is acute myeloid leukemia.